Labiana Health (XMAD:LAB) Gross-Profit-to-Asset % : 42.37% (As of Dec. 2022)

View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Labiana Health's annualized Gross Profit for the quarter that ended in Dec. 2022 was €28.80 Mil. Labiana Health's average Total Assets over the quarter that ended in Dec. 2022 was €67.97 Mil. Therefore, Labiana Health's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2022 was 42.37%.

Labiana Health Gross-Profit-to-Asset % Historical Data

The historical data trend for Labiana Health's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Gross-Profit-to-Asset % Chart

Labiana Health Annual Data

Trend

Dec20

Dec21

Dec22

Gross-Profit-to-Asset %

51.59

52.10

50.54

Labiana Health Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22
Gross-Profit-to-Asset %	-	-	50.82	42.37

Competitive Comparison of Labiana Health's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Labiana Health's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Labiana Health's Gross-Profit-to-Asset % falls into.

Labiana Health Gross-Profit-to-Asset % Calculation

Labiana Health's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	32.633	/	( (68.367	+	60.779)	/ 2 )
	=	32.633	/	64.573
	=	50.54 %

Labiana Health's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2022 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Dec. 2022 ))	/ count )
	=	28.796	/	( (75.163	+	60.779)	/ 2 )
	=	28.796	/	67.971
	=	42.37 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2022) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Labiana Health Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Labiana Health's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Labiana Health (XMAD:LAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Gross-Profit-to-Asset %

Traded in Other Exchanges

N/A

Address

Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023

Website

https://www.labiana.com

Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.